25 February 2021
Latham & Watkins Advises the Underwriters in Halozyme Therapeutics’ Private Offering of Convertible Notes
Advising firms
Deal team
6 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Greg Rodgers Lead | Latham & Watkins LLP | Partner | capital markets | New York |
| Michael Sullivan Lead | Latham & Watkins LLP | Partner | capital markets | San Diego |
| Jacob Steele | Latham & Watkins LLP | Associate | capital markets | Not stated |
| Andrew Blumenthal | Latham & Watkins LLP | Associate | capital markets | Not stated |
| Nicholas Reist | Latham & Watkins LLP | Associate | capital markets | Not stated |
| Ty Balzer | Latham & Watkins LLP | Associate | capital markets | Not stated |
3 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 700m (US$700 million)
- What the figure measures
- Issue size
- Client
- Not stated
- Counterparties
- Halozyme Therapeutics, Inc. (Issuer)